Rain brings winter chill to Delhi
The government has revoked patents granted to US company Allergan for two glaucoma drugs, the latest in a series of setbacks for Western firms in India's fast-expanding pharmaceutical market.
The patent appeal board revoked two of the company's patents on medicines for treatment of glaucoma, an illness that damages the optic nerve.
According to a notice posted on the website of the Intellectual Property Appellate Board, the drugs Ganfort and Combigan do not stand the "test of innovation" and are ineligible for patents.
Last week, it revoked patents related to GlaxoSmithKline's breast cancer drug Tykerb that would have delayed the launch of generic versions of the medicine for two-and-half years to 2021.